| Myasthenia Gravis, Generalized
Soliris vs Rystiggo
Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.Deep comparison between: Soliris vs Rystiggo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRystiggo has a higher rate of injection site reactions vs Soliris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rystiggo but not Soliris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Soliris
Rystiggo
At A Glance
IV infusion
Every 2 weeks
Complement C5 inhibitor
SC injection
Once weekly (6-week cycles)
FcRn blocker
Indications
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
- Myasthenia Gravis, Generalized
Dosing
Paroxysmal nocturnal hemoglobinuria 600 mg IV infusion weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (adults) 900 mg IV infusion weekly for 4 weeks, then 1200 mg at week 5, then 1200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized (pediatric) Weight-based IV infusion dosing; induction and maintenance doses vary by body weight (5 kg to >=40 kg), administered every 2 to 3 weeks after induction.
Myasthenia Gravis, Generalized Weight-based SC infusion once weekly for 6 weeks: less than 50 kg: 420 mg (3 mL); 50 to less than 100 kg: 560 mg (4 mL); 100 kg and above: 840 mg (6 mL); administer at up to 20 mL/hour; subsequent cycles based on clinical evaluation, no sooner than 63 days from start of previous cycle.
Contraindications
- Unresolved serious Neisseria meningitidis infection
—
Adverse Reactions
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, sinusitis, upper respiratory tract infection, diarrhea, vomiting, hypertension, musculoskeletal pain, abdominal pain, peripheral edema, pyrexia, arthralgia, influenza, contusion
Serious Meningococcal infections, other serious infections, disease exacerbation after SOLIRIS discontinuation, thrombosis, infusion-related reactions
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria sicca/subflava, Neisseria spp unspecified), cholestatic or mixed pattern liver injury in aHUS patients
Most common (>=10%) headache, infections, diarrhea, pyrexia, hypersensitivity reactions, nausea
Serious infections (including fatal pneumonia), aseptic meningitis
Postmarketing herpes zoster
Pharmacology
Eculizumab is a monoclonal antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH, complement-mediated thrombotic microangiopathy in aHUS, and presumed reduction of terminal complement C5b-9 deposition at the neuromuscular junction in gMG and in NMOSD.
FcRn antagonist; rozanolixizumab-noli is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing circulating IgG levels and pathogenic AChR and MuSK autoantibody concentrations in patients with generalized myasthenia gravis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Soliris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Rystiggo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Soliris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rystiggo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Soliris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Rystiggo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Soliris.
Cost estimate not availableAccessia Health: Myasthenia Gravis - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SolirisView full Soliris profile
RystiggoView full Rystiggo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.